Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 2985-2995

  Brune, Kay ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

COX 2; Diclofenac; Ibuprofen; Mode of action; Pharmacokinetics; Tissue accumulation

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; KETOPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; PIROXICAM; PROPYPHENAZONE; SALICYLIC ACID; TENOXICAM; VALDECOXIB;

BLOOD VESSEL WALL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HALF LIFE TIME; HEART; HUMAN; INFLAMMATION; KIDNEY PARENCHYMA; LOW DRUG DOSE; PAIN; PROTEIN BINDING; REVIEW; STOMACH ULCER; SYNOVIAL FLUID; TISSUE DISTRIBUTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUGS, NON-PRESCRIPTION; FEMALE; HUMANS; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL;

EID: 37749043907     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242584     Document Type: Review

References (80)

1. Bjordal JM, Ljunggren AE, Klovning A, Slørdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritis knee pain: meta analysis of randomised controlled trials. BMJ 2004;329:1317
2. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55
3. Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord 2004;5:28
4. Moore RA, Tramer MR, Carroll D, et al. Quantitive systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998;316:333-8
5. van Tulder MW, Scholten RJPM, Koes BW, Deyo RA. Non-steroidal anti-inflammatory drugs for low-back pain. The Cochrane Database of Syst Rev 2000;CD000396[2], DOI: 10.1002/14651858
6. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999;128:1121-32
7. Vane J. The mechanism of action of anti-inflammatory drugs. Int J Clin Pract Suppl 2003;135:2
8. Vane JR. Aspirin and other anti-inflammatory drugs. Thorax 2000;55:S3-9
9. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992;89:7384-8
10. Bhattacharyya DK, Lecomte M, Dunn J, et al. Selective inhibition of prostaglandin endoperoxide synthase-1 (cycloogygenase-1) by valerylsalicylic acid. Arch Biochem Biophys 1995;317:19-24
11. Dewitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993;95:40-4S
12. Meade EA, Smith WL, Dewitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-14
13. Hoffmann C. COX-2 in brain and spinal cord implications for therapeutic use. Curr Med Chem 2000;7:1113-20
14. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-10
15. McAdam BF, Mardini IA, Habib A, et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 2000;105:1473-82
16. Smith WL, Meade EA, Dewitt DL. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann NY Acad Sci 1994;714:136-42
17. Zeilhofer HU. Prostanoids in nociception and pain. Biochem Pharmacol 2007;73:165-74
18. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96: 7563-8
19. Henry D, Lim LL-Y, García Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6
20. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
21. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84
22. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74
23. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;331:1310-16
24. Solomon DH, Avorn J, Sturmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006;54:1378-89
25. Brune K. Clinical relevance of nonsteroidal anti-inflammatory drug pharmacokinetics. Eur J Rheumatol Inflamm 1987;8:18-23
26. Day RO, McLachlan AJ, Graham GG, Williams KM. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999;36:191-210
27. Dreiser RL, Marty M, Ionescu E, et al. Relief of acute low back pain with diclofenac-K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo-controlled trial. Int J Clin Pharmacol Ther 2003;41:375-85
28. Niethard FU, Gold MS, Solomon GS, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol 2005;32:2384-92
29. Zacher J, Burger KJ, Färber L, et al. [Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden's and/or Bouchard's nodes). Double-blind, controlled, randomized study]. Akt Rheumatol 2001;26:7-14
30. Green S, Buchbinder R, Barnsley L, et al. Non-steroidal antiinflammatory drugs (NSAIDs) for treating lateral elbow pain in adults. The Cochrane Database of Syst Rev 2001;CD003686[4], DOI: 10.1002/14651858.CD003686
31. Evans JMM, McMahon AD, McGilchrist MM, et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: record linkage case control study. BMJ 1995;311:22-6
32. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs. An update for clinicians. A scientific statement from the American Heart Association. Circulation 2007;115:1634-42
33. Grillo MP, Knutson CG, Sanders PE, et al. Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile. Drug Metab Dispos 2003;31:1327-36
34. Brechbühler S, Riess W. Biopharmaceutical comparison of oral dosage forms of Voltaren and Cataflam and of their active ingredients in man. Ciba-Geigy Report B113/1996. 1986
35. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 1997;33:184-213
36. Williams K, Day R, Knihinicki R, Duffield A. The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem Pharmacol 1986;35:3403-5
37. Giuliano F, Warner TD. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol 1999;126:1824-30
38. Tegeder I, Lotsch J, Krebs S, et al. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther 1999;65:533-44
39. Moore N. Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. Clin Drug Investig 2007;27:163-95
40. Willis JV, Kendall MJ, Flinn RM, et al. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 1979;16:405-10
41. Riess W, Schmid K, Botta L, et al. [The percutaneous absorption of diclofenac]. Arzneimittelforschung 1986;36:1092-6
42. Geisslinger G, Dietzel K, Bezler H, et al. Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Toxicol 1989;27:324-8
43. Cordero JA, Alarcon L, Escribano E, et al. A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs. Pharm Sci 1997;86:503-8
44. Singh P, Roberts MS. Skin permeability and local tissue concentrations of non-steroidal anti-inflammatory drugs after topical application. J Pharm Exp Ther 1994;268:144-51
45. Dreiser RL. Topical antirheumatic drug therapy: current practice and future trends. Eur J Rheumatol Inflamm 1994;14:3-8
46. Sioufi A, Pommier F, Boschet F, et al. Percutaneous absorption of diclofenac in healthy volunteers after single and repeated topical application of diclofenac Emulgel. Biopharm Drug Dispos 1994,15:441-9
47. Benson MD, Aldo-Benson M, Brandt KD. Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis. Semin Arthritis Rheum 1985;15:65-7
48. Hinz B, Dormann H, Brune K. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 2006;54:282-91
49. Rainsford KD, Schweitzer A, Brune K. Autoradiographic and biochemical observations on the distribution of non-steroid anti-inflammatory drugs. Arch Int Pharmacodyn Ther 1981;250:180-94
50. Riess W, Stierlin H, Degen P, et al. Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. Scand J Rheumatol 1978;22:17-29
51. Dutta SK, Basu SK, Sen KK. Binding of diclofenac sodium with bovine serum albumin at different temperatures, pH and ionic strengths. Indian J Exp Biol 2006;44:123-7
52. Elmquist WF, Chan KKH, John VA, Sawchuk RJ. Transsynovial distribution of diclofenac. Pharm Res 1989;6:S-212
53. Elmquist WF, Chan KK, Sawchuk RJ. Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. Pharm Res 1994;11: 1689-97
54. Fowler PD. Voltarol: diclofenac sodium. Clin Rheum Dis 1979;5:427-64
55. Fowler PD, Shadforth MF, Crook PR, John VA. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharmacol 1983;25:389-94
56. Fowler PD, Dawes PT, John VA, Shotton PA. Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100mg slow-release formulation. Eur J Clin Pharmacol 1986;31:469-72
57. Liauw H, Walter S, Lee L, Ku E. Effects of diclofenac on synovial eicosanoid product formation in arthritic patients. J Clin Pharmacol 1985;25:455-74
58. Radermacher J, Jentsch D, Scholl MA, et al. Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol 1991;31:537-41
59. Brune K, Rainsford KD, Wagner K, Peskar BA. Inhibition of anti-inflammatory drugs of prostaglandin production in cultured macrophages. Naunyn Schmiedebergs Arch Pharmacol 1981;315:269-76
60. Ku EC, Kothari H, Lee W, et al. Effects of diclofenac sodium on arachidonic acid metabolism. Agents Actions Suppl 1985;17:189-93
61. Liauw HL, Ku E, Brandt KD, et al. Effects of Voltaren on arachidonic acid metabolism in arthritis patients. Agents Actions Suppl 1985;17:195-9
62. Urquhart E. A comparison of synovial fluid concentrations of non-steroidal anti-inflammatory drugs with their in vitro activity. Agents Actions 1991;32:261-5
63. Caruso I, Moro E, Patrono C, et al. Plasma and synovial fluid pharmacokinetics and prostaglandin inhibitory effect of indoprofen in patients with rheumatoid arthritis. Scand J Rheumatol 1980;9:123-6
64. Day RO, Francis H, Vial J, et al. Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. J Rheumatol 1995;22:2295-303
65. Dromgoole SH, Furst DE, Desiraju RK, et al. Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis. Clin Pharmacol Ther 1982;32:371-7
66. Kurowski M, Dunky A, Geddawi M. Effects of pirazolac on arachidonic metabolism in the human synovial system. Curr Med Res Opin 1987;10:494-501
67. Seppälä E, Nissilä M, Isomäki H, et al. Effects of non-steroidal anti-inflammatory drugs and prednisolone on synovial fluid white cells, prostaglandin E2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis. Scand J Rheumatol 1990;19:71-5
68. Tokunaga M, Ohuchi K, Yoshizawa S, et al. Change of prostaglandin E level in joint fluids after treatment with flurbiprofen in patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1981;40:462-5
69. Davies NM, Skjodt NM. Choosing the right nonsteroidal antiinflammatory drug for the right patient: a pharmacokinetic approach. Clin Pharmacokinet 2000;38:377-92
70. Lin JH, Cocchetto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1987;12:402-32
71. Avdeef A. Assessment of distribution-pH profiles. In Pliska V, Testa B, van de Waterbeemd H, eds. Lipophilicity in Drug Action and Toxicology. New York: VCH Publishers, 1996
72. Graf P, Glatt M, Brune K. Acidic nonsteroid anti-inflammatory drugs accumulating in inflamed tissue. Experientia 1975;31:951-3
73. Pratico D, Dogne JM. Selective cyclooxygenase-2 inhibitors development in cardiovascular medicine. Circulation 2005;112:1073-9
74. Brune K, Glatt M, Graf P. Mechanisms of action of antiinflammatory drugs. Gen Pharmacol 1976;7:27-33
75. Weaver ML, Flood DJ, Kimble EF. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclooxygenase-2 inhibitors. Ann Rheum Dis 2003;62:378
76. Brune K, Furst DE. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? Rheumatology (Oxford) 2007;46:911-19
77. Chlud K, Wagener HH. [Percutaneous therapy with non-steroidal anti-inflammatory drugs. Pharmacokinetic criteria of effectiveness]. Fortschr Med 1991;109:59-60
78. Gondolph-Zink B, Gronwald U. Active substance concentration in articular and periarticular tissues of the knee joint after cutaneous application of diclofenac-diethylammonium emulgel. Aktuelle Rheumatol 1996;21:298-304
79. Kurowski M, Abt G, Dittmar K, et al. Pharmacokinetics of two topical diclofenac preparations. Z Allgemeinmed 1998;74:999-1003
80. Rolf C, Engstrom B, Beauchard C, et al. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (Oxford) 1999;38:564-7